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1. Introduction 
Implantable Loop Recorder (ILR) or Insertable Cardiac Monitor (ICM) is a tool developed in 
the 1990’s which allows permanent monitoring of cardiac rhythm during a period exceeding 
one year. The major interest of this new tool is to establish a closed correlation between 
symptoms and heart rhythm. The first application of ICM was the diagnosis of recurrent 
syncope. Syncope is a common disorder which may recur and impair the survival and the 
quality of life of the patients. The objective of the investigation of syncope is to diagnose the 
cardiac aetiology because the mortality in this case is high. About half of the patients 
implanted with an ICM complains of a new syncope and about 50% of these patients had 
documented cardiac rhythm disturbances. The most frequent is a sinus bradycardia or sinus 
arrest but these results depend on the age of patients, resting ECG abnormalities and 
structural cardiac disease. A classification of the mechanisms of recurrent syncopes has been 
defined with the results of the ISSUE study separating the syncope due to primary cardiac 
arrhythmia from neurally-mediated syncope and from unknown syncope. The analysis of 
the presyncopal phase on the ICM restored ECG allows physicians to adapt the treatment 
(antiarrhythmic (with 2 h) agents or pacemaker) and optimize the programming of the 
pacemaker when necessary. It is recommended to implant the ICM early in the syncope 
patients with a normal physical examination, normal ECG and without structural heart 
disease and negative tilt testing. In the presence of cardiac disease, it is recommended to 
implant the ICM after performing an electrophysiological study and tilt testing. In syncope 
patients with depressed left ventricular ejection fraction, the implantation of an automatic 
implantable cardiac defibrillator is preferable. Early application of an ICM reduces the cost 
of the investigation of the patients suffering from syncope, especially when the 
electrophysiological study is avoided.  The indications of the ICM tend to be extended to 
new syncope populations such as pediatric patients, the epileptic population and older 
patients suffering from unexplained falls. New algorithms are developed by the 
manufacturers which allow a good analysis of electrical atrial activity and open new 
applications of the ICM in the managements of patients treated for atrial arrhythmias. 
2. Syncopes and unexplained recurrent syncopes 
Syncope is a common disorder with an annual incidence of 1.3-2.7 episodes/1000 per year. 
Recurrent syncopes are also frequent, accounting for 3% of emergency visits and 1% of 
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hospital admissions in the US. The diagnosis of cardiac syncope remains the principal 
objective in these patients because the mortality rates exceed 30% in this subgroup of 
patients (Kapoor et al., 1983; Soteriades et al., 2002). However, their diagnosis is often 
difficult, leading to repetitive hospitalizations and clinical investigations. About 40% of 
diagnoses are established after the related history is considered and a meticulous physical 
examination and resting ECG recorded, but in 60% the diagnosis is probable or uncertain. 
The applications of the laboratory investigations are limited. The ambulatory ECG of 24 or 
48 hours identified a rhythmic aetiology in 19% of cases; the electrophysiological study is 
only useful in patients with underlying structural cardiac disease or resting ECG 
abnormalities (Task force 2004; Strickberer et al., 2006). Tilt table testing is useful to provoke 
neurally-mediated syncope, but its specificity and sensitivity are still debated (Moya et al., 
2001). Exercise stress testing is not recommended except in stress induced syncope. 
Neurological testings are also not recommended (Task force 2004; Moya et al., 2009).  Since 
clear recommendations published in 2004 and 2009 about the diagnosis strategy of syncope 
a median of 13 performed tests per patient has been reported in a recent large prospective 
study before considering ICM implantation (Edvardsson et al., 2011).  
After complete investigations, recurrent syncopes remain undiagnosed in about 20 – 30% 
(Krahn et al., 1999a; Brignole et al., 2005a; Vitale et al., 2010). The gold standard for the 
diagnosis of an arrhythmic event is the ECG recording during a syncopal episode which can 
be obtained by a prolonged ECG recording. The first developed method was the external 
loop recorder but patient compliance is low and the duration is limited to a few weeks. 
About 20 % of the patients failed to activate their loop recorder properly, resulting in an 
undiagnosed test (Sivakumaran et al., 2003). The second method is the implantable loop 
recorder which now allows for a monitoring of cardiac rhythm over three years. This 
method of investigation for recurrent syncope is recommended by the Task force (Task 
force, 2004; Moya et al., 2009). A recent study estimated that ICM should be implanted in 
two thirds of the patients suffering from unexplained recurrent syncopes (Vitale et al., 2010) 
but only 18 % of these patients were implanted. Although the ICM has been recognized as a 
useful tool in the diagnosis of recurrent syncopes in the latest guidelines for the 
management of recurrent syncope it is always underutilized.   
3. Methods 
3.1 Principle 
We describe for example the first device manufactured for the market. It is a small (62x19x8 
mm) titanium box of 9 cm3 in volume and weighing 17 g. The ICM is a single-lead ECG 
recording device with an initial battery life of 14 months (Reveal® 9525, 9526 Medtronic 
USA, Minneapolis) and which is now 36 months (Reveal® DX 9528 Medtronic USA, 
Minneapolis). The two sensing bipoles are separated by a distance of 37 mm. For the most 
recent device the bipolar electrocardiogram signal is stored in a circular memory of 49.5 
minutes. After spontaneous symptoms, the memory is frozen with a patient assistant: 6.5 
minutes of the preceding ECG signal are stored and 1 minute after activation. Three 
spontaneous episodes can be stored. The rhythmic events can be automatically stored in 
accordance with the alert programmed limits (27 episodes – 0.5 minutes pre and 0.5 minutes 
post-activation). The ECG can be retrieved by a standard programmer (Medtronic 2090, 
Medtronic USA, Minneapolis) (figure 1). New detection algorithms proved their efficiency 
to detect the presence of atrial arrhythmias (Reveal® XT, Medtronic USA, Minneapolis) 
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(Hindricks et al., 2010) and will participate in the extension of the indications of the ICM 
implantation to patients suffering from palpitations, atrial fibrillation etc...  
Others devices (Paruchuri et al., 2011) are in development by others manufacturers 
(Confirm ILR, St Jude Medical and Sleuth ILR, Transoma Medical, Arden Hills, MN). 
 
 
sensing poles
apart 37 mm
A B
C D
 
Fig. 1. A. Insertable cardiac monitor. B Reveal patient assistant in the pocket of the patient. 
C. Reveal Vector Check helps the physician to define the optimal implantation site based on 
the signal detection. D. Example of ECG recording with the Reveal Vector Check. 
3.2 Implantation technique and positions (anterior chest or left axillary) 
The ICM is easily inserted in the left chest using a local anesthetic with thorough asepsis in 
an operating room. A pocket is fashioned and the device is inserted with the electrodes 
towards the skin. The best implantation site is vertically to the right or left of the sternum 
between the fourth and the fifth intercostal spaces (Zellerhoff et al., 2000) (figure 2). With the 
latest version (Reveal DX) we can use the Reveal Vector Check to confirm the optimal 
implantation site based on signal detection. Sometimes an unusual site can be chosen, such 
left axillary implantation (figure 2). Miracapillo et al implanted 10 patients with an ICM in 
axillary position with success. The high R-wave amplitude obtained in this position was 
higher than with the standard position. The quality of the ECG recorder was always 
excellent and always allowed easy diagnosis interpretation (Miracapillo et al., 2010). This 
site of implantation might be very useful in younger patients for aesthetic reasons but also 
in obese patients to improve the amplitude of the R-wave recorded.  
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Fig. 2 Left. Anteroposterior chest radiography displays Reveal in a usual site. Right. Chest 
radiography shows Reveal inserted in a left axillary site in a young girl.   
3.3 Program parameters and control 
After implantation, the ICM is programmed. In the latest version of ICM, sensing and 
detection are automatically programmed (dynamic sensing threshold). Physicians can 
optimize the sensing of R-waves by adjusting the sensitivity parameters. Automatic ECG 
memory storage of episodes is activated by the physician (fast ventricular tachycardia, 
ventricular tachycardia, asystole, bradycardia) and the upper limits are defined. We can 
customize the detection criteria for each type of episode.  Activation by the patient after 
syncope is possible with the Patient Assistant. 
3.4 Follow up  
Regular interrogation of the device is adviced to detect symptomatic or non-symptomatic 
arrhythmias or paroxysmal bradycardia. However for the past months it has been possible 
to control the ICM by telecardiology. This technology has several advantages, the control is 
permanent, the patient remains at home and the alerts are chosen by the cardiologist 
depending upon the clinical characteristics of the patient.  
3.5 False positive recording or limits of the method 
Five to 30 % of patients failed to appropriately activate the device after syncope. That was a 
problem with the first generation of the device which has disappeared with the newer 
generations of the device. The second and third generations have the ability to record an 
event either automatically or by manual activation. The effectiveness of the automatic 
activation has been evaluated by Ermis et al. in 50 patients. The auto-activation mode was 
found to be more efficient in documenting arrhythmia episodes than the manual activation 
mode (48% arrhythmia versus 6%) (Ermis et al., 2003).  One limit of the ICM is related to the 
transient loss of signal which generates a false flat baseline tracing (figure 3). A false 
ventricular pause can also be recorded with the latest generation of ICM characterized by an 
autodetection sensing of the QRS. The change in the R wave amplitude leads to their 
undersensing. Conversely, the oversensing of myopotential noises can lead to the detection 
of false ventricular tachycardia or fibrillation (Figure 4). The second limit of the ICM is the 
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lack of contemporary recording of blood pressure values. Neurally-mediated syncopes are 
not always associated with bradycardia, but exclusive vasodepressor response is possible. 
These kinds of syncope cannot be diagnosed with the ICM nor the syncope linked to the 
modification or adjustment to the upright position. The exact nature of the syncope remains 
unknown in these conditions.  
 
 
 
Fig. 3. Transient loss of signal which generates a false flat baseline tracing indicated as 
asystole in absence of presyncope or syncope.  
 
 
Fig. 4. Paroxysmal oversensing of R waves confounded to myopotentiels (Reveal® 9528). 
Fast ventricular tachycardia is the diagnosis retained by the device.  
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4. ICM implanted for recurrent syncopes 
4.1 Results 
Initially, the implantation of the ICM was limited to patients with recurrent syncopes and 
thorough negative investigations including an electrophysiological study. After the 
implantation of the ICM about 50% of the patients complained of a new syncope (Krahn et 
al., 1999a; Nierop et al., 2000; Lombardi et al., 2005; Pierre et al., 2008; Entem et al., 2009). 
The syncope is correlated to a rhythmic event in about 50% of cases (Table 1). These results 
are confirmed in the largest registry published in 2011 (PICTURE registry): 38 % of recruited 
patients complained of a recurrent syncope whose 59 % have a cardiac aetiology 
(Edvardsson et al., 2011). 
  
Authors 
Patients 
n 
Syncope recurrence 
n (%) 
Rhythmic event 
n (%) 
Krahn 1999a 85 58 (68.2) 21(42) 
Nierop 2000 35 14 (40) 8 (57) 
Seidll 2000 133 83 (62) 32 (39) 
Chettaoui 2002 32 15 (46.8) 10 (71) 
Pierre 2008 95 43 (45.2) 27 (62.8) 
Entem 2009 140 54 (38.5) 33 (64.5) 
Edvardsson 2011 650 218 (38) 128 (59) 
Table 1. Frequency of recurrent syncope and rhythmic events in ICM patients 
The most frequent recorded event is a sinus arrest or bradycardia (figure 5); a complete 
atrio-ventricular block is less frequent (figure 6) and tachycardia is rare (figures 7, 8). Sinus 
bradycardia or sinus arrest account for the majority of the rhythmic events, and the duration 
of the events is widely variable (Table 2) (Chenet al., 2008). The ventricular pause can be 
severe, lasting up to 70 seconds (Babuty et al., 2001). 
 
Authors Syncope 
Rhythmic 
event 
Bradycardia AVB SupraVT VT others 
Krahn 
1999a 
58 21 18 ? 3   
Nierop 
2000 
14 14 4 ? 4   
Seidl 2000 83 32 22 ? 6 3 1 
Krahn 2001 30 11 10  1  3 
Chettaoui 
2002 
15 21 2 ? 5 3  
Brignole 
2005b 
22 17 3 14    
Pierre 2008 43 27 16 5 2 4  
Entem 2009 51 33 18 9 2 4  
Table 2. Arrhythmic events documented by ICM 
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However these results depend upon the patient’s age: in older patients arrhythmic events 
are more frequent (3.1 higher probability of an arrhythmia) (Brignole et al., 2005a). In 
patients older than 65 years of age, complete atrio-ventricular block accounts for 53% of 
arrhythmia events.   
 
 
Fig. 5. Symptomatic sinus arrest during 9 seconds  
 
 
Fig. 6. Reveal’s auto-activation captured a ventricular pause due to complete 
atrioventricular block. P waves are indicated by black stars.  
The timeframe for recurrent symptoms shows that most events occur shortly after the 
implantation of the ICM: 31% within 30 days, 50% within 2 months, 78% within 6 months 
and 93% within one year (Assar et al., 2003).  
Syncope is more likely to be associated with an arrhythmia than presyncope. Krahn et al 
reported a higher incidence of arrhythmic events in the group of patients suffering from 
syncope (64%) than in the group suffering from presyncope (25%) (Krahn et al., 1999a, 
2001a).  
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Fig. 7. Left. Symptomatic paroxysmal supraventricular tachycardia (black star). The 
electrophysiological demonstrated the atrioventricular nodal  reentrant tachycardia. Right. 
Presyncope due to fast irregular tachycardia with wide QRS recorded in a patient without 
structural heart disease. During the electrophysiological study a right functional bundle 
branch block was induced by rapid atrial pacing. Atrial fibrillation was the final diagnosis 
and the patient was successfully treated with an  antiarhythmic drug. 
The International Study on Syncope of Uncertain Etiology (ISSUE) proposed a classification of 
spontaneous syncope documented by an implantable loop recorder (Brignole et al., 2005b) 
dependent on the mechanism of syncope (Table 3). The advantage of this classification is that 
of separating the syncope due to primary cardiac arrhythmia (Type 1C, type 4 B, 4C, 4D) from 
neurally-mediated syncope (type 1A, 1B, type 2) and from unknown syncope (type 3). 
However this classification probably overestimated the number of neurally-mediated syncope 
because some sick sinus syndrome patients are included in type 2. 
 
Arrhythmia Mechanism
Type 1 Asystole (pause ≥ 3 seconds)
Type 1A Sinus arrest initiated by progressive bradycardia 
or tachycardia 
Type 1B Sinus bradycardia and AV block 
Type 1C AV block sudden with concomitant increase in 
sinus rate 
Neurally-mediated syncope 
 
 
Neurally-mediated syncope 
Primary cardiac arrhythmia 
Type 2 Bradycardia
Type 2A decrease of heart rate > 30 % 
Type 2B Heart rate < 40 for 10 seconds 
Neurally mediated syncope 
Type 3 No or slight rhythm variations Unknown
Type 4 Tachycardia increase in heart rate > 30 % or > 120 /min 
Type 4A progressive sinus tachycardia 
 
Type 4B atrial fibrillation 
Type 4C supraventricular tachycardia 
Type 4D ventricular tachycardia 
 
Inadaptation to the upright 
position 
Primary cardiac arrhythmia 
Primary cardiac arrhythmia 
Primary cardiac arrhythmia 
Table 3. The ISSUE classification of ECG-documented spontaneous syncope 
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Fig. 8. Syncope due to fast ventricular tachycardia. Note the change of the QRS morphology 
at the beginning of the tachycardia.   
4.2 Influence of resting ECG and structural heart disease on results of ICM recordings 
One generally analyzes with caution the patients suffering from syncope in the presence of 
abnormalities on resting ECG or in the presence of structural heart disease. The Task force 
defined some electrocardiographic conduction abnormalities suggesting an arrhythmic 
syncope: bifascicular block, QRS duration ≥ 0.12 s, Mobitz I atrio-ventricular block, sinus 
bradycardia <50/min, or sinus pause ≥ 3s, non-sustained ventricular tachycardia, Pre-
excited QRS complexes and T wave abnormalities suggesting a primary electrical disease 
(Moya et al., 2009).  However, some of these abnormalities are frequent and may not justify 
the implantation of a definitive pacemaker (Epstein et al., 2008) in the absence of infrahissian 
conduction disturbance or inducible arrhythmias recorded during the electrophysiological 
study. We recently reported in populations with a normal infrahissian conduction time that 
arrhythmic events were not more frequent in syncope patients with cardiac conduction 
abnormalities on resting ECG (Pierre et al., 2008) than in patients without them (27.5% 
versus 28.7%). Paroxysmal complete atrio-ventricular block remains rare in this selected 
population (13.7% versus 1.5%). That was explained by the high frequency of symptomatic 
sinus arrest in the group of patients without cardiac conduction abnormalities on resting 
ECG and the very low frequency of complete atrio-ventricular block in bifascicular block 
defined by right bundle branch block and left axis deviation (Nierop et al., 2000; Brignole et 
al., 2001; Pierre et al., 2008).  
However caution should be exercised in the presence of right bundle branch block 
associated with right axis deviation. In this case, the frequency of complete paroxysmal 
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atrio-ventricular block is high (36%) (Brignole et al., 2001). At the present time, patients with 
recurrent syncopes and right bundle branch block and right axis deviation are usually 
implanted with a permanent pace maker without prior implantation of the ICM (Epstein et 
al., 2008).  
In the risk of stratification at the initial evaluation of syncope, the presence of cardiovascular 
disease and /or history of congestive heart failure are considered as major risk factors 
accounting for 3 points in EGSYS score and 1 point in OESIL score and these parameters are 
recognized as a predictive factor for cardiac arrhythmia in the latest guidelines for the 
diagnosis and the management of syncope (Task Force 2004; Moya et al., 2009). However, 
this conclusion cannot be applied to patients having recurrent syncopes and having 
undergone profound clinical cardiac investigation, especially when electrophysiological 
studies were unremarkable (Table 4). Several studies with the ICM demonstrated that 
cardiac arrhythmia was not correlated to the presence of structural heart disease (Mason et 
al., 2003; Solano et al., 2004; Pierre et al., 2008; Pezawas et al., 2008) in patients with recurrent 
syncopes. An arrhythmic event was documented more frequently in patients without 
structural heart disease than in patients with structural heart disease (33.7 % versus 9.5 %)  
(Pierre et al., 2008).This significant difference was not observed in other studies (Mason et 
al., 2003; Pezawas et al., 2008). The aetiology of arrhythmia is controversial with regard to 
the presence or absence of structural heart disease:  Solana et al reported a greater 
prevalence of primary cardiac arrhythmia (atrioventricular block and ventricular 
arrhythmia) in patients with structural heart disease than in patients without structural 
heart disease (sinus arrest primarily) (Solano et al., 2004). In contrast Pierre et al (Pierre et 
al., 2008) observed only one AV block and no ventricular arrhythmia in structural heart 
disease patients.  
However, we must specify that in these studies, most patients with structural heart disease 
have normal or limited alteration of left ventricular ejection fraction (Menozzi et al., 2002). 
We should be cautious in patients with severe depressed left ventricular ejection fraction. In 
this population, the implantation of an automatic implantable defibrillator has to be 
discussed because the probability of severe ventricular arrhythmia is high (Epstein et al., 
2008).  
 
Authors 
Cardiac disease 
Documented arrhythmia 
(%) 
Without Cardiac disease 
Documented arrhythmia 
(%) 
Mason 2003 31 29 
Solano 2004 52 28 
Pierre 2008 9.5 33.7 
Pezawas 2008 45 51 
Table 4. Documented arrhythmia in patients with or without structural heart disease 
4.3 Interest of ICM in patients without structural heart disease and normal ECG 
Moya was the first author to report the results of ICM in patients suffering from recurrent 
syncopes with a normal physical examination and normal ECG without structural heart 
disease. These syncopes evoke a neuro-mediated mechanism. In this study (ISSUE), the rate 
of recurrence was high (34%) and the major arrhythmic event documented in the ICM was 
prolonged asystole (> 3 secondes) regardless of the results of the tilt-testing (Moya et al., 
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2001). Typically, a progressive sinus bradycardia precedes a ventricular asystole due to 
sinus arrest. Most of the asystolic pauses were very long at the time of the syncope (from 15 
± 6 to 17 ± 9 seconds). These findings suggested that the syncope was neurally-mediated 
with a strong cardioinhibitory reflex. Deharo et al observed no correlation between the heart 
rhythm recorded by the ICM during a spontaneous vasovagal syncope and the heart rhythm 
recorded during the tilt testing or the ATP test (Deharo et al., 2006). ICM appears to better 
define the therapeutic strategy in these patients in accordance with heart rhythm 
contemporary to the syncope. The implantation of a definitive pacemaker in the group of 
patients with severe bradycardia proved its efficiency in preventing the recurrence of 
syncopes (only 0.05 episodes per patient per year) (Brignole et al., 2006). A multicenter 
prospective, double-blind randomized placebo-controlled study (ISSUE 3) is underway to 
assess the effectiveness of pacemaker therapy for syncopal asystolic pause (ISSUE 3, 2007).   
4.4 Value of asymptomatic arrhythmias in unexplained syncope 
The major interest of the ICM is to establish a closed correlation between symptoms and 
ECG. However long-term monitoring of patients with unexplained syncope with the ICM 
demonstrated frequent severe arrhythmic events (Krahn et al., 2004). Severe asymptomatic 
arrhythmia was documented in 15% of patients in Krahn’s study: sinus bradycardia, 
atrioventricular block, supraventricular tachycardia and ventricular tachycardia. Specific 
treatment resulted in the resolution of syncope. Asymptomatic arrhythmias are often 
clinically relevant, especially in syncope patients leading to pacemaker implantation in the 
case of bradycardia or ICD in case of ventricular tachycardia (Epstein et al., 2008). The 
guidelines of 2009 (Moya et al., 2009) retained the following diagnosis criteria in the absence 
of a clear correlation between symptoms and ECG monitoring: ECG monitoring is 
diagnostic when periods of Mobitz II or III degree AV block or ventricular pause > 3 s or 
rapid prolonged paroxysmal supraventricular tachycardia or ventricular tachycardia are 
detected. Caution should be considered with the possible exception of young trained 
persons, during sleep, medical patients, or rate-controlled atrial fibrillation.  
4.5 ICM in diagnosis and management of syncope: Theory and practice 
The first reports on ICM demonstrated the superiority of the ICM in terms of diagnosis over 
the conventional diagnostic testing. In the RAST trial including 60 recurrent syncope 
patients, a diagnosis was obtained in 43% of the patients randomized to ICM compared to 
20% in the patients undergoing conventional diagnostic testing (Krahn et al., 2001). The 
Eastbourne Syncope Assessment Study recruited 201 patients randomized in the 
conventional investigation group (n=98) and ICM group (n=103). The superiority of the ICM 
in terms of diagnosis was evident: 42% versus 7% (hazard ratio for time to ECG diagnosis 
was 6.53). Moreover, the time to ECG directed therapy was quicker for the ICM group than 
for the conventional group (Farwell et al., 2006). The diagnosis performance of ICM depends 
on the duration of the follow-up and the segments of the patients. It varied from 27 to 50%. 
ICM is especially powerful in older patients: a diagnosis was made for every 1.7 patients 
selected for ICM implantation in Brignole’s study (Brignole et al., 2005a). 
In the recommendations published in 2004 and revisited in 2009, the ICM implantation is 
recommended in two kinds of situations: firstly the ICM implantation appears early in 
patients with recurrent syncope of uncertain origin without high risk criteria and a high 
likelihood of recurrence of syncope within battery longevity of the ICM (class IB). Secondly 
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the ICM implantation is recommended in high risk patients in whom a comprehensive 
evaluation did not demonstrate a cause of syncope or lead to a specific treatment (class IB). 
Generally in patients with a normal physical examination, normal ECG and without familial 
history of sudden cardiac death and  structural heart disease and negative tilt testing, the 
implantation of ICM must be considered early in the presence of recurrent syncope.  
Selective use of an electrophysiological study and tilt testing must be discussed before 
implanting the ICM (Garcia-Civera et al., 2003).  In the presence of cardiac disease or high 
risk criteria suggesting arrhythmic syncope as defined in the 2009 guidelines, it is 
recommended to implant ICM after performing an electrophysiological study and tilt 
testing (Moya et al., 2009). Several studies previously discussed in this chapter 
demonstrated the benefit of a strategy based on a relatively straightforward initial clinical 
evaluation: the early implantation of an ICM and a therapy delivered in accordance with the 
arrhythmic event documented during an episode of recurrent syncope (Brignole et al., 
2005a, Pierre et al., 2008). The analysis of the presyncopal phase on the ICM restored ECG 
allows physicians to adapt and optimize the programming of the pacemaker when 
necessary (Brignole et al., 2007).   
Table 5 summarized the recommendations of the implantation of the ICM in unexplained 
recurrent syncope. Vitale et al reported in a multicenter study a discrepancy between 
clinical practice and standardized indications for the ICM in patients with unexplained 
syncope (Vitale et al., 2010) whereas no clinical characteristics distinguished the patients 
receiving the ICM or not. Only 18% of patients received an ICM whereas 69% of patients 
had appropriate criteria for implantation of an ICM. In this study the ICM strategy allowed 
8.7 higher likelihood of ECG diagnosis. This study underlines the underutilization of ICM in 
the diagnosis of syncope.  
 
Recommendations of ICM Class Level 
Early phase of evaluation in patients with 
recurrent syncope of uncertain origin, absence 
of high risk criteria and high likelihood of 
recurrence within battery longevity of the 
device 
I B 
High risk patients in whom a comprehensive 
evaluation did not demonstrate a cause of 
syncope or lead to a specific treatment 
I B 
Should be considered to assess the 
contribution of bradycardia before embarking 
on cardiac pacing in patients with suspected 
or certain reflex syncope presenting with 
frequent or traumatic syncopal episodes  
IIa B 
Table 5. Recommendations of Implantable Cardiac monitor in accordance to the 2009 
guidelines (Moya et al.; 2009) 
4.6 ICM in particular populations 
4.6.1 ICM in children and young adults 
As we have previously noted, in children the ICM implantation can be safety implanted in 
the left axillary region for aesthetic reasons.  Only a few experiences with the ICM in a 
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paediatric setting have been published. Two studies reported the results in children 
suffering from recurrent syncopes. Results similar to those of adults are obtained in 
children. A high degree of symptom-rhythm correlation was established. In the Sreeram 
study (Sreeram et al., 2008), 15/33 patients had documented arrhythmic events which 
required specific therapy. In Babikar’s study of the 15 patients who experienced symptom 
recurrence, 8 (53%) had an arrhythmic event (polymorphic ventricular tachycardia n=1, 
supraventricular tachycardia n=5, sinus arrest n=1 and Mobitz II AV block =1) (Babikar et 
al., 2008). Al Dharhi et al reported 64% of diagnosis in 42 children implanted with ICM (Al 
Dharhi et al., 2009). Further studies are needed to confirm the benefit of ICM in the 
paediatric population and to confirm its tolerability.  
4.6.2 ICM in older patients  
Falls are a major health care concern in elderly patients. About 30 % of people over 65 years 
fall once. The falls can unmask recurrent syncopes (Kenny et al., 2001; Amstrong et al., 2003). 
Some overlap between syncopes and falls has been recognized in the elderly population. 
Several parameters explain this confusion between falls and syncope: the interrogation, the 
amnesia for loss of consciousness and the difficulty to investigate these patients. Moreover 
falls are often unwitnessed, rendering the diagnosis of fall more difficult. The ICM is a simple 
tool that can be used early in the diagnostic strategy. In a small study reported by Amstrong 
about half of patients who activated their Reveal documented cardiac arrhythmias 
(bradycardia and ventricular tachycardia) (Amstrong et al., 2003). In the SAFE PACE study, a 
strong correlation between non-accidental falls and cardio-inhibitory carotid sinus 
hypersensitivity has been established (Kenny et al., 2001). The bradycardia induces 
hypotension which favours the instability of old patients leading to falls without loss of 
consciousness. In the absence of positive carotid sinus massage, the ICM can document 
bradycardia preceding the fall. The consequence for these patients is of great interest because 
the implantation of a definitive pacemaker dramatically reduced the injurious events.  
4.6.3 J wave syndromes and syncope  
Brugada syndrome and early repolarization are primary electrical diseases responsible for 
sudden death by ventricular fibrillation. Implantation of an ICD in secondary prevention is 
a class I recommendation (Epstein et al., 2008), but in primary prevention its implantation is 
controversial because a high incidence of complications linked to the ICD was observed in 
this young population (Sacher et al., 2006). Brugada syndrome and early repolarization are 
two electrocardiographic criteria that must suggest a diagnosis of cardiac arrhythmia in 
patients complaining from syncope (Moya et al., 2009). Nevertheless, the mechanism of 
syncope may be heterogeneous in these subgroups of patients and the differential between 
benign and malignant forms of syncope is not always very easy.  The implantation of the 
ICM has been proposed by some authors especially when the characteristics of syncope 
were not convincing or the primary implantation of an ICD is refused by the patient. In the 
early repolarization syndrome the implantation of an ICD is only indicated in patients with 
documented ventricular arrhythmias. ICM can be used in other symptomatic patients.  
4.6.4 Epileptic patients, “convulsive syncope” and ICM  
Two problems remain unexplained in the epileptic population: the overlap between 
convulsive syncope and epilepsy and the high frequency of sudden death.  Convulsive 
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syncope is defined as cerebral anoxic seizure activity secondary to transient global 
impairment of blood flow, often difficult to differentiate from epilepsy. Sudden death is 
higher in the epileptic population than in the general population and frequently syncopes 
remain unexplained in the epileptic population despite adequate doses of anticonvulsant 
drugs (Tomson et al., 2008).  Several hypotheses have been evoked amongst them the 
cardiovascular cause. Cardiologic investigations in this population reported an alternative 
diagnosis in 40% of cases (Zaidi et al., 2000a). Two types of clinical events have been 
demonstrated in this population. The first is a cardiac event linked to seizure, the second is a 
primary cardiac event. ICM can be useful to diagnose a cardiac event in these selected 
patients. Twenty patients with refractory epilepsy received an ICM in order to record heart 
rhythm during seizure (Rugg-gunn et al., 2004). 377 episodes were analyzed and 
bradycardia and sinus arrest occurred in 8 recorded events (2.1%) but this represented four 
patients (21%). These bradycardia are linked to temporal seizure (ictal bradycardia). The 
mechanism may be parasympathetic activation. We recently reported that syncopal 
bradycardia could be the first manifestation of epilepsy (Dinan et al., 2008). Videotelemetry 
monitoring with electroencephalography is the gold standard for diagnosing this particular 
form of epilepsy. The implantation of a pacemaker has been proposed to prevent death and 
disability (Zaidi et al., 2000a). The second mechanism is a neurocardiogenic syncope. In 
some patients, the neurocardiogenic syncope can result in convulsive syncope which can be 
difficult to distinguish from epilepsy. Despite a careful clinical investigation and laboratory 
tests including head upright tilt table testing, sometimes it is uncertain to conclude on the 
nature of the syncope. In this situation IMC is a power tool to display the cardiac rhythm 
during convulsive episodes (Kanjwal et al., 2009). Frequently a prolonged asystole or 
paroxysmal atrio-ventricular block was reported. The neurally-mediated mechanism is 
suspected in these patients because a slowing of heart rhythm was recorded before the 
asystole episode. The second argument is the inefficacity of the anti epileptic drugs and the 
disappearance of seizure after implantation of a dual chamber pacemaker in these patients.  
It is important to diagnose the cardiac origin of a convulsive syncope in order to avoid a 
long term anticonvulsant treatment which is expensive, inefficient and can cause serious 
morbidity.  
5. Cost-effectiveness of ICM in syncope patients 
Syncope is a symptom with an extensive differential diagnosis which can be roughly 
divided into cardiac syncope, neurally-mediated syncope, orthostatic hypotension and 
vascular steal syndromes (Moya et al., 2009). Consequently there is no single diagnostic test 
and more often, many laboratory tests (24 hours ambulatory ECG, tilt testing, 
electrophysiological study and echocardiography) are done, but their sensitivity and 
specificity are low. These laboratory tests significantly add to the overall cost, but their 
contribution to the diagnostic yield is low. About 40 % of patients referred to the emergency 
department are hospitalized. Referred and hospitalized patients are known to generate a 
cost estimated between $3,000-25,000, a mean cost of $5400 per hospitalization in USA and 
€3506 in Italy (Moya et al.; 2009). The recording of the heart rhythm during the syncopal 
episode remains the only means to diagnosis an arrhythmic aetiology. Preliminary studies 
demonstrate the economic benefit of the ICM compared to the conventional strategy in 
reducing the cost of the diagnosis of syncope (Krahn et al.; 1999b; Zaidi et al.; 2000b; Ermis 
et al., 2003). The RAST study has the objective of comparing the cost of both strategies. In 
www.intechopen.com
 Implantable Loop Recorder in Clinical Practice 
 
127 
this study, the cost of a primary implantable loop recorder strategy is 26% less than that of 
conventional testing (Krahn et al., 2001b). Early application of ICM reduces the cost per 
patient ($1,878 versus 2,355 and per diagnosis $3,756 versus 5,045). In the EaSyAS study, the 
overall costs tended to be lower in the ICM group than in the conventional investigation 
group (Farwell et al., 2006).  
6. Others applications of ICM - Diagnosis of atrial fibrillation 
A new algorithm is proposed in the last version of ICM leading to a specific analysis of the 
atrial electrical activity and to improving the diagnosis of atrial fibrillation. This new device 
(Reveal® XT, Medtronic Inc, Minneapolis USA) has a good sensitivity (96.1%) and 
specificity (85.4%) for identifying patients with atrial fibrillation (Hindricks et al., 2010).  
Some teams already use these ICM after atrial fibrillation ablation in order to detect the 
recurrence of the arrhythmia. Such data offered a safer guide to continue or stop the 
anticoagulation and antiarrhythmic drugs (Pokushalov, et al., 2011). The application of this 
diagnosis method demonstrated in CARISMA study a high incidence of new-onset atrial 
fibrillation in patients recently hospitalized for myocardial infarction with left ventricular 
dysfunction (Jons, et al., 2011). The risk of major cardiovascular events in patients with new-
onset atrial fibrillation longer than 30 seconds was increased (HR=2.04) suggesting to treat 
these atrial fibrillation episodes. The implantation of the old version of the ICM has been 
already proposed in other domains than syncope. About 50 % of strokes in young patients 
remain unexplained after non invasive investigations. One suspected diagnosis in this 
population is the occurrence of asymptomatic paroxysmal atrial fibrillation which can’t be 
detected by the standard ECG or 24 hours ambulatory ECG. Some authors proposed to 
analyze the atrial vulnerability during an electrophysiological study but its specificity and 
sensibility are not defined in the prospective study. Dion et al tested the interest of the ICM 
(second generation Reveal Plus 9526) in young patients suffering from unexplained stroke.  
In this study the ICM did not display a high prevalence of atrial arrhythmias but the 
population was selected and the implantation was only performed three months after the 
stroke (Dion et al., 2010). Another limit of this study was the criteria to retain the diagnosis 
of atrial fibrillation which was an irregular tachycardia with narrow QRS complex. The 
application of the new algorithm to detect atrial arrhythmias in larger population of patients 
with unexplained stroke should be of great interest because the detection of symptomatic or 
not atrial fibrillation involves starting an oral anticoagulation. A new large randomized 
prospective study (CRYSTAL AF) is ongoing to evaluate the long term monitoring with  the 
implantation of a subcutaneous cardiac monitor (Reveal XT) in patients with cryptogenic 
stroke (Sinha, AM.; 2010). Results are expected at the end of 2012. In the population of 
patients suffering from recurrent syncope or palpitations this new algorithm could also be 
useful to improve the diagnosis. 
7. Conclusion 
ICM or ILR is a new tool still underused in clinical practice. The longevity of the battery 
allows prolonged cardiac monitoring which is the most suitable investigation to correlate 
the symptom to an arrhythmic event.  Recurrent syncope is the major indication of ICM 
implantation. Recurrent syncope may impair the survival and the quality of life of the 
patients, the capacity to work and the ability to drive. A long-term monitoring strategy with 
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the ICM yields more diagnoses than with conventional testing. Early application of ICM is 
now recommended in patients with recurrent syncopes in order to diagnose the mechanism 
of the syncopes and to guide the effective therapy. New applications of the ICM are in 
development, especially in patients suffering from atrial fibrillation and in patients suffering 
from unexplained palpitations.  
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certain efforts towards developing of biologic pacemakers through tissue engineering and studying of cell
synchronization are discussed. The main attention is paid to implementations of pacemakers in different
medical situations oriented towards widening the clinical indications for implanting the cardiac pacemakers.
New methods and devices in cardiac resynchronization therapy (CRT) have received particular attention.
Placing of pacing electrodes has been treated soundly. Furthermore, emerging of complexities and
complications in new clinical situations and other safety problems have been discussed thoroughly. The
authors have derived the used information from their own clinical practice and experiences of their medical
colleagues. These and other pragmatic features can be acknowledged as the most valuable asset of the book.
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